

山东威高集团医用高分子制品股份有限公司
Shandong Weigao Group Medical Polymer Company Limited

环境政策
Environmental Policy

1. 承诺 | Commitment

适用实体承诺遵守环境法律法规、预防污染、提高资源效率、应对气候变化并持续改进环境绩效，在医疗产品质量和患者安全不受影响的前提下减少产品生命周期和运营活动的环境影响。

The Reporting Entities are committed to complying with environmental law, preventing pollution, improving resource efficiency, addressing climate change and continually improving environmental performance, while reducing the life-cycle and operational impacts of medical products without compromising product quality or patient safety.

2. 适用范围 | Scope

除非相关政策另有说明，本政策适用于山东威高集团医用高分子制品有限公司、其于中国成立的附属公司以及在报告边界内的美国介入医疗产品制造业务（统称“适用实体”）。

Unless otherwise stated, this Policy applies to Shandong Weigao Group Medical Polymer Company Limited, its PRC subsidiaries Argon Medical's US interventional medical products manufacturing business within the reporting boundary (collectively, the "Reporting Entities").

本政策覆盖自有运营，并通过供应商行为准则、采购要求和合作协议对重要供应商、承包商及业务伙伴提出环境期望。

This Policy covers own operations and sets environmental expectations for material suppliers, contractors and business partners through the Supplier Code, procurement requirements and agreements.

3. 环境管理体系及治理 | Environmental Management System and Governance

- 各适用实体应建立与其规模和风险相适应的环境管理体系，明确责任、法律清单、风险评估、操作控制、应急响应、培训、监测、内部审计及管理评审。具备条件的基地应推进 ISO 14001 或等效认证。

Each Reporting Entity shall maintain an environmental management system proportionate to its size and risk, defining responsibilities, legal registers, risk assessment, operational controls, emergency response, training, monitoring, internal audit and management review. Sites should pursue ISO 14001 or equivalent certification where appropriate.

- 本公司企业管委员会批准本政策、目标和重大投资；基地负责人对合规和绩效负责；EHS 部门汇总数据并至少每年向治理机构报告。

The Corporate Governance Committee of the Company shall approve this Policy, related targets and material investments. Site leaders are accountable for policy implementation, compliance and performance. EHS shall consolidate relevant data and report at least annually to the Board of Directors or an appropriate governing body.

- 适用实体应在制定或实施重大环境措施时，适当听取员工、监管机关、客户、供应商和受影响社区等外部利益相关者意见。

The Reporting Entities shall appropriately consult employees, regulators, customers, suppliers, affected communities and other external stakeholders when developing or implementing material environmental measures.

4. 气候、能源和温室气体 | Climate, Energy and Greenhouse Gases

适用实体应测量主要能源使用和范围 1 及范围 2 排放，逐步筛查重大范围 3 类别，设定有基准年、覆盖范围和期限的减排及能源效率目标，并优先采用节能、可再生能源和低碳工艺。

The Reporting Entities shall measure material energy use and Scope 1 and Scope 2 emissions, progressively screen material Scope 3 categories, set emissions-reduction and energy-efficiency targets with a baseline, coverage and timeframe, and prioritise efficiency, renewable energy and lower-carbon processes.

5. 水、废水及水资源 | Water, Effluent and Water Resources

各基地应识别取水来源、水压力和主要用水环节，计量取水、排放和循环利用，预防污染，遵守排放标准并设定重点基地的节水目标。洁净生产、清洗、冷却及工艺用水应实施风险导向优化。

Each site shall identify water sources, water stress and major uses; measure withdrawal, discharge and recycling; prevent pollution; comply with discharge standards; and set water-efficiency targets for priority sites. Clean production, washing, cooling and process water shall be optimised on a risk basis.

6. 废弃物、材料和循环性 | Waste, Materials and Circularity

- 按照预防、减量、再使用、回收、能源回收和安全处置的优先顺序管理废弃物，并按危险/非危险及最终处理方式记录数量和承包商去向。
Manage waste according to the hierarchy of prevention, reduction, reuse, recycling, energy recovery and safe disposal, recording quantities and contractor destinations by hazardous or non-hazardous classification and final treatment method.
- 医用塑料、药品包装、金属边角料、化学品容器、电子部件及其他重点材料应实施减量、再生材料、可回收设计和合规处置评估，同时确保无菌、屏障、机械性能、可追溯性及患者安全。
Medical plastics, pharmaceutical packaging, metal scrap, chemical containers, electronic components and other priority materials shall be assessed for reduction, recycled content, recyclable design and compliant disposal while maintaining sterility, barrier performance, mechanical performance, traceability and patient safety.
- 危险废物必须由合格承包商运输和处置，并保留转移联单、许可证、称重和最终处理证明。
Hazardous waste must be transported and treated by qualified contractors, with manifests, permits, weights and final-treatment evidence retained.

7. 污染、化学品及灭菌相关影响 | Pollution, Chemicals and Sterilisation-related Impacts

适用实体应控制空气污染物、挥发性有机物、粉尘、噪声、温室气体、废水污染物及化学品风险。使用灭菌气体或其他高影响工艺的基地应监测泄漏和排放、维护控制设备、制定应急计划并评估更低影响替代方案。

The Reporting Entities shall control air pollutants, volatile organic compounds, dust, noise, greenhouse gases, effluent pollutants and chemical risks. Sites using sterilisation gases or other high-impact processes shall monitor leaks and emissions, maintain control equipment, establish emergency plans and assess lower-impact alternatives.

8. 产品设计、采购和生物多样性 | Product Design, Procurement and Biodiversity

- 研发和产品管理应在不影响安全和法规合规的前提下考虑材料效率、包装优化、使用寿命、可维修性、可回收性、受限物质及生命周期影响。
R&D and Product Management shall consider material efficiency, packaging optimisation, service life, repairability, recyclability, restricted substances and life-cycle impacts without compromising safety or regulatory compliance.
- 采购应将环境许可、认证、能源/排放、水、废物、化学品和材料来源纳入重点供应商评估。
Procurement shall include environmental permits, certification, energy and emissions, water, waste, chemicals and material sourcing in assessments of priority suppliers.
- 适用实体应对自有场址和主要原材料开展生物多样性相关性筛查；如识别出重大依赖或影响，应制定地点或采购层面的缓解措施。

The Reporting Entities shall screen own sites and major raw materials for biodiversity relevance and, where material dependencies or impacts are identified, establish site- or sourcing-level mitigation measures.

9. 目标、培训、监测及披露 | Targets, Training, Monitoring and Disclosure

适用实体应制定并公开分阶段环境目标，至少覆盖能源/温室气体、水和废弃物，并披露基准、边界、进展、方法和重大变化。相关员工和承包商应接受与其职责相适应的培训。

The Reporting Entities shall set and publish phased environmental targets covering at least energy and greenhouse gases, water and waste, disclosing baselines, boundaries, progress, methods and material changes. Relevant employees and contractors shall receive role-appropriate training.